AKCEA THERAPEUT (NASDAQ:AKCA)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $17.33 and last traded at $17.33, with a volume of 472,105 shares changing hands. The stock had previously closed at $15.08.

Several equities analysts have weighed in on the company. BMO Capital Markets assumed coverage on AKCEA THERAPEUT in a research report on Tuesday, August 8th. They issued an “outperform” rating and a $25.00 target price for the company. Stifel Nicolaus assumed coverage on AKCEA THERAPEUT in a research report on Tuesday, August 8th. They issued a “buy” rating and a $19.00 target price for the company. Wells Fargo & Company assumed coverage on AKCEA THERAPEUT in a research note on Tuesday, August 8th. They issued an “outperform” rating and a $27.00 price objective for the company. Finally, Cowen and Company assumed coverage on AKCEA THERAPEUT in a research note on Tuesday, August 8th. They issued an “outperform” rating for the company.

The company’s market capitalization is $1.11 billion. The stock’s 50-day moving average is $11.44 and its 200 day moving average is $11.44.

In related news, major shareholder Ionis Pharmaceuticals Inc bought 3,125,000 shares of the stock in a transaction dated Wednesday, July 19th. The stock was acquired at an average price of $8.00 per share, for a total transaction of $25,000,000.00. Following the completion of the purchase, the insider now owns 28,884,540 shares in the company, valued at $231,076,320. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/22/akcea-therapeut-akca-hits-new-12-month-high-at-17-33.html.

AKCEA THERAPEUT Company Profile

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.